Drug Class Review: Proton Pump Inhibitors: Final Report Update 5 [Internet]

Review
Portland (OR): Oregon Health & Science University; 2009 May.
Drug Class Reviews.

Excerpt

Proton pump inhibitors decrease secretion of gastric acid. They act by blocking the last enzyme in the system that actively transports acid from gastric parietal cells into the gastrointestinal lumen, hydrogen–potassium adenosine triphosphatase, also known as the proton pump. Omeprazole, the first drug in this class, was introduced in 1989. Since then, 4 other proton pump inhibitors have been introduced: lansoprazole (1995), rabeprazole (1999), pantoprazole (2000), and esomeprazole (2001). In 2003 omeprazole became available over-the-counter in the United States. The purpose of this review is to compare the benefits and harms of different PPIs.

Publication types

  • Review

Grants and funding

The Drug Effectiveness Review Project, composed of 15 organizations including 14 state Medicaid agencies and the Canadian Agency for Drugs and Technology in Health commissioned and provided funding for this report. These organizations selected the topic of the report and had input into its Key Questions. The content and conclusions of the report were entirely determined by the Evidence-based Practice Center researchers. The authors of this report have no financial interest in any company that makes or distributes the products reviewed in this report.